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Background
The Schizophrenia Outpatient Health Outcomes (SOHO)
study is a 3-year, prospective, outpatient, observational
study of health outcomes associated with antipsychotic
treatment. 10,972 patients were enrolled upon initiation
of or change to a new antipsychotic in actual outpatient
treatment settings.
Material and Methods
Response in positive, negative, cognitive, depressive and
overall symptoms from baseline to 6 months, as meas-
ured using CGI (Clinical Global Impression) scales, was
assessed for patients enrolled in SOHO. Mean change in
weight and Body Mass Index (BMI) from baseline to 6
months was also assessed. Sexual adverse events were col-
lected by the physician using a patient-reported question-
naire with three options (no problems, some problems
and unable to perform). A logistic regression model,
adjusted for baseline covariates, compares the odds
responding/having sexual adverse events in the olanzap-
ine cohort with each of the other cohorts
Results
6-month data had been collected on 9,028 patients with
schizophrenia. Olanzapine (58%), clozapine (59%) and
two or more antipsychotics (2+APs; 56%) cohorts had the
highest proportion of patients who responded in terms of
their overall symptoms [Other cohorts (range depot
(41%) to risperidone (51%)]. The odds of responding in
overall symptoms, at 6 months, in the olanzapine cohort
compared with the other treatment cohorts were: risperi-
done (Odds Ratio: 1.32; 95% CI: 1.16–1.49), quetiapine
(1.77; 1.48–2.12), amisulpride (1.60; 1.22–2.08), oral
typical (1.60; 1.32–1.92) and depot typical (1.86; 1.49–
2.32) cohorts. No statistical differences were observed
between the olanzapine cohort and the clozapine (0.87;
0.68–1.13) and 2+AP's (0.89; 0.65–1.22) cohorts. Similar
results were observed for response in positive, negative,
cognitive and depressive symptoms and the EQ-VAS
health state. Social functioning improved across all
cohorts; the odds of being socially active in the olanzap-
ine cohort compared to the other treatment cohorts were:
risperidone (1.28; 1.06–1.55), quetiapine (1.66; 1.28–
2.15), oral typical (1.71; 1.29–2.26) and depot typical
(1.59; 1.15–2.21) cohorts. No statistical differences were
observed between the olanzapine cohort and the amisul-
pride (1.15; 0.73–1.79), clozapine (1.25; 0.87–1.80) and
2+AP's (0.71; 0.44–1.15) cohorts.
Mean weight change between baseline and 6 months
across cohorts ranged from 0.7 ± 5.0 kg for quetiapine
treated patients to 2.4 ± 4.9 kg for olanzapine treated
patients. Mean change in BMI between baseline and 6
months ranged from 0.3 ± 1.8 kg/m2 for quetiapine
treated patients and 0.3 ± 1.7 kg/m2 for oral typical treated
patients to 0.8 ± 1.7 kg/m2 for olanzapine treated patients
and 0.8 ± 1.9 kg/m2for clozapine treated patients. The
odds of patients having problems with their sexual func-
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tioning in the olanzapine cohort compared to the other
treatment cohorts were: risperidone (odds ratio: 0.71;
95% CI: 0.61–0.82), oral typical (0.66, 0.53–0.82) and
depot typical (0.68; 0.52–0.90) cohorts. No statistically
significant differences were observed between the olanza-
pine cohort and the quetiapine (0.96; 0.78–1.19), amisul-
pride (0.78; 0.56–1.08), clozapine (1.13; 0.85–1.50) and
2+AP's (0.73; 0.50–1.07) cohorts.
Discussion
After 6 months of treatment, patients in the olanzapine
cohort were more likely to improve in terms of clinical sta-
tus and social functioning compared with patients in the
risperidone, quetiapine, oral typical and depot typical
cohorts. No differences were observed between the olan-
zapine and the clozapine and 2+AP's cohorts. From base-
line to 6 months, weight gain occurred across all
antipsychotic treatment cohorts with olanzapine treated
patients experiencing more weight gain than patients
treated with other antipsychotics. Findings suggest that
patients in the olanzapine, quetiapine, amisulpride, cloz-
apine and 2+AP's are less likely to develop problems with
their sexual functioning compared with patients in the
other cohorts.Page 2 of 2
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